# Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

> **NCT05813470** · PHASE3 · COMPLETED · sponsor: **Cinnagen** · enrollment: 256 (actual)

## Conditions studied

- Allergic Asthma
- Uncontrolled Moderate to Severe

## Interventions

- **BIOLOGICAL:** Omalizumab (CinnaGen)
- **BIOLOGICAL:** Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)

## Key facts

- **NCT ID:** NCT05813470
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-18
- **Primary completion:** 2023-01-15
- **Final completion:** 2023-01-15
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813470, "Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05813470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*